Retatrutide + Cagrilintide blend_Dosage, benefits & legal status
Also known as Retatrutide + Cagrilintide, Cagrilintide + Retatrutide, GLP-3 + Cagrilintide, reta cagri
An unapproved triple agonist paired with an amylin analog, tested by nobody.
Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is Retatrutide + Cagrilintide blend?
Plain language first. The technical label stays, but it never stands alone.Overview
Two weight-loss compounds in one vial, copying a pairing that was tested with a different, approved drug. Nobody has trialled this version, and one syringe means you cannot adjust one without the other.
A research-market co-formulation of retatrutide, an investigational GLP-1 / GIP / glucagon triple agonist, with cagrilintide, a long-acting amylin analog. Typically supplied at a 1:1 ratio. No clinical trial of this combination has been registered or published. The mechanistic rationale is extrapolated from the cagrilintide plus semaglutide program.
What it's used for
An injected blend sold for weight loss, combining a triple agonist still in trials with an amylin analog.
How does Retatrutide + Cagrilintide blend work?
What it does in the body, and where.The reasoning is borrowed from CagriSema, which is a real trialled product, and applied to a compound that has not finished its own trials.
- 01Two different appetite systemsRetatrutide is a triple agonist at the GLP-1, GIP and glucagon receptors. Cagrilintide is a long-acting amylin analog. Amylin and GLP-1 signal fullness through partly separate routes, which is the argument for combining them.
- 02CagriSema is the proof of concept, and it used semaglutideThe REDEFINE program tested cagrilintide with semaglutide, an approved drug with a known dose. Substituting retatrutide changes the tested half of the pair for an untested one.
- 03Two titration schedules in one syringeBoth components are normally increased slowly and separately to manage nausea. A fixed-ratio vial makes that impossible without changing the dose of both at once.
Where this compound is thought to act.
What else is it used for?
Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
- Weight loss, which is what both components are developed forResearch only
- Copying the CagriSema pairing with an unapproved agonistnone
The published record
Papers and trials about Retatrutide + Cagrilintide blend
12 papers tagged human · 1 not reviews or lab · 0 clinical trial publications
Furthest stage reached: No clinical trial on record
Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count.
At a glance
Four things to know about Retatrutide + Cagrilintide blend
Evidence
Category
Weight loss and metabolic
Common vial
Varies
Half-life
Both components are long-acting, and the blend has no figure of its own
How much, and do you cycle it?
The range, and whether you take breaks.Research only, weekly, by convention. Not established for the blend No range
No schedule has been studied for this combination. The components have different clearance times and different conventional frequencies, so a single shared schedule is a convenience of the vial rather than a finding.
Both components are long-acting, and the blend has no figure of its ownNo figure
Retatrutide and cagrilintide are each designed for weekly dosing. A blend has no single half-life. Each component clears on its own schedule, so one draw starts two or more different clocks. See each component's page.
You can compare this against the whole library to see where it sits.
How do I dose and price it?
Enter your vial and your dose. Pick a mix. We show the draw and the cost.The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.
Sold most often as a 10/10 mg vial, sometimes listed under the vendor code GLP-3 for the retatrutide half. The ratio is the filler's choice. No trial has established a ratio for this pairing, because no trial of this pairing exists.
Pick your vial to see concentrations and a draw.
Choose your mix
Measuring the water1 mL = one full 100-unit syringe.
Your draw
What one draw delivers
The same arithmetic as the calculator, worked out for the vials vendors sell.Dose anchored to Retatrutide, at the 2 to 12 mg per week people commonly cite. Each table assumes one draw per week. If you split it across more injections, divide the reading by the number of injections.
| Retatrutide dose | 1 mL water | 2 mL water | 3 mL water |
|---|---|---|---|
| 2 mg | 20.0 units
| 40.0 units
| 60.0 units
|
| 12 mg | Over 100 units: will not fit one U-100 syringe.
| Over 100 units: will not fit one U-100 syringe.
| Over 100 units: will not fit one U-100 syringe.
|
No published human study establishes a dose for this combination. Open each component's page for the ranges its own trials used.
A 1:1 vial couples every retatrutide titration step to an identical cagrilintide step. Retatrutide is titrated slowly because its gastrointestinal side effects are dose-limiting, and cagrilintide has its own nausea profile. In one vial the two cannot be adjusted separately, which removes the main tool for managing either.
Retatrutide + Cagrilintide blend starts at $108.00 across 4 vendors, typically $5.25 – $13.33 per mg.
5 listings, last read Oct 11, 2026. Shipping and card fees are not included.
How do you store it?
Before mixing, and after.Dry powder in the freezer or fridge. Once mixed, fridge, and use within about a month.
Unmixed lyophilized Retatrutide + Cagrilintide blend keeps for a long time cold. Once you add water the clock starts: most reconstituted vials hold up for roughly 28 to 30 days at fridge temperature. Keep it out of light, and do not freeze it after mixing.
What are the side effects and cautions?
Known cautions and warnings for this compound.Who should avoid it
- Pregnancy or breastfeeding
- A personal or family history of medullary thyroid carcinoma, or MEN 2, which is a contraindication for this drug class
- A history of pancreatitis
- Anyone who wants established safety data, because none exists for this combination in humans
Stop and get help
- Severe or persistent abdominal pain, which can signal pancreatitis
- Vomiting that stops you keeping fluids down
- Signs of an allergic reaction, including facial or throat swelling or trouble breathing
- A lump or swelling in the neck, hoarseness, or trouble swallowing
Common effects
- Nausea, especially in the first weeks
- Vomiting and constipation or diarrhea
- Reduced appetite, which is the intended effect
- Injection site reactions
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is Retatrutide + Cagrilintide blend approved?
And where the numbers on this page come from.No. Retatrutide + Cagrilintide blend is not approved for any use, anywhere. It is sold labeled for laboratory research only, and there is no legal route to buy it for human use.
- Approval statusResearch only
- RouteUnder the skin (subcutaneous)
- Checked24 August 2026
- DoseFrom community reports. No regulator or trial established this dose.
- Vial sizeFrom what vendors typically list; not a recommendation.
- SourcesNone traced yet.
What has happened recently
We have not yet written a full regulatory note for this compound. The status above is current as of the date shown.
You can compare this against the whole library, or read how to check a seller.
What else is like Retatrutide + Cagrilintide blend?
Others in Amylin analogs, side by side.If you're weighing Retatrutide + Cagrilintide blend, it's worth reading Amycretin, ASC36, and AZD6234 in the same class.
An unapproved triple agonist paired with an amylin analog, tested by nobody.
- Dose
- Research only
- How often
- Weekly, by convention
An experimental two-in-one weight-loss compound, as a pill or a shot.
- Dose
- 0.3 up to 60 mg per week
- How often
- Once weekly (injected)
An experimental amylin drug from Hong Kong-listed Ascletis, with rat and monkey data only and an undisclosed structure.
- Dose
- No human dose disclosed
- How often
- Monthly injection or daily tablet (intended)
An experimental weekly fullness-hormone shot from AstraZeneca, tuned to the amylin receptor.
- Dose
- Once weekly in trials; milligram dose levels have not been publicly disclosed
- How often
- Weekly
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
No primary source has been traced for this compound yet. Treat everything on this page as unverified until one is. How we grade evidence
Beyond these, 23 records are indexed. Browse the records